Compare FMC Corp (FMC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs GeneDx Holdings Corp — how do they compare? FMC Corp trades at $8.35 (market cap $1.39B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and FMC Corp pays a 3.59% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and GeneDx Holdings Corp for 19 Days on average.
| FMC | WGS | |
|---|---|---|
Market Cap | $1.39B | $2.02B |
Volume | 4,145,979 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $167.51 |
52-Week Low | $8.44 | $34.51 |
Typical Hold Time | 68 Days | 19 Days |
Enterprise Value | $5.19B | $2.05B |
Dividend Yield | 3.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC stock trades at $8.35, down 8.14% on the day, reflecting bearish technical signals and weak profitability. Despite a low P/S ratio of 0.34 and recent earnings beats, the company reported a net income margin of -84.83% in 2025. Recent news includes a regulatory filing in Brazil for a new herbicide and a minority equity investment by Tessenderlo Group.
The outlook remains challenging due to high debt and cyclical headwinds, though management's deleveraging efforts and a consensus price target of $14.60 suggest potential upside. Key risks include persistent negative margins, volatile cash flows, and industry pressures.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
